Twelve cancers, one blood draw. That is the scope Natera put in front of the FDA — and on October 9, 2026, the agency granted its multi-cancer early detection assay Breakthrough Device designation.

The designation moves the test into an accelerated review lane. It does not approve it. It does not prove the test saves lives.

Natera's assay reads cell-free DNA circulating in the blood and looks for patterns associated with cancer. When it granted the designation, the FDA reviewed data across 12 cancer types and weighed three measures: sensitivity, specificity, and cancer signal origin — the test's ability to name where a detected signal likely started.

Cancer signal origin carries the most operational weight. A positive result that cannot point to a probable source sends a patient into a broad, expensive workup. Sensitivity without origin is a referral queue. Origin without sensitivity misses exactly the cancers that have no guideline screen today.

📊
What the FDA weighed

12 cancer types in the review dataset

Sensitivity — does the test find cancer when it is there

Specificity — does it stay quiet when it is not

Cancer signal origin — can it say where the signal came from

What a breakthrough designation actually buys

The Breakthrough Devices program is reserved for technologies aimed at life-threatening conditions with no adequate alternative. Designated products get more frequent meetings with the FDA and a prioritized review. It is a process commitment, not a clinical result.

Natera's own language reflects that. Alexey Aleshin, the company's chief medical officer for oncology and early cancer detection, framed the designation as an accelerant: "we look forward to working with the FDA as we aim to detect cancer earlier, when it's easier to treat." A colleague, director Jordan Stricker, was blunter on LinkedIn. The designation, he wrote, "is not a marketing authorization."

The assay itself is built on the same substrate as the rest of Natera's platform: short fragments of tumor DNA that leak into plasma and can be read without a tissue sample. The screening version looks for methylation patterns rather than a single mutation, which is what lets one tube of blood cover a dozen tumor types at once. The hard part was never finding those fragments. It is separating a real early signal from the noise that a healthy immune system, age, and inflammation produce every day.

That distinction matters because the previous decade of cancer diagnostics left a graveyard of tests that found more disease and helped less. As we wrote in October, a survival figure can outlive the trial that produced it — the PDS0101 readout is the most recent reminder.

The question the whole field still owes an answer

MCED is a crowded lane. GRAIL's Galleri and Exact Sciences are chasing the same premise: catch cancer in blood before symptoms appear, when treatment is cheaper and more likely to work. Detecting a signal is not the same as extending survival, and the field is still waiting on the one number that proves it does.

The first hard evidence arrived this year. NHS-Galleri — the first randomized trial of any multi-cancer blood test, run across more than 140,000 people in England — missed its primary endpoint of reducing stage III and IV cancers combined. Stage IV diagnoses did fall by more than a fifth in the second and third screening rounds, and the test roughly quadrupled the cancer detection rate when added to standard screening.

That is a real but partial result. The primary endpoint came back negative. The cancer-specific mortality data that would settle the argument is not due for three to six years after the final screen.

Screening earns its place by reducing deaths. The history of the category is full of tests that increased detection without changing outcomes, and payers price that risk into every coverage decision.

Why Natera can afford to wait

Natera is not a screening-first company. Its commercial base is Signatera, a tumor-informed test that tracks recurrence after treatment, plus its women's health and organ health products. Extending a cell-free DNA platform into screening is an adjacency, not a pivot. The market treated the news as incremental, and the stock barely moved.

A designation opens a conversation with the FDA. It does not open a reimbursement code. Payers will want outcome data before covering a screening test for adults with no symptoms, and that data takes years to accumulate.

Twelve cancers is a scope claim. The number that will decide this program is the one no one has measured yet: how many deaths it prevents.

Natera's FDA breakthrough designation for its MCED assay
The primary announcement: the assay, the 12-cancer dataset, and the three performance measures the FDA reviewed.
Natera investor relations
The company's own framing — and its explicit note that the designation is not a clearance or approval.
FDA grants breakthrough device designation for Natera's multi-cancer early detection assay
The wire copy as it ran, with the date and the designation language intact.
FT.com company announcements
Useful for the exact regulatory wording: a designation, not an authorization.
Natera's MCED designation, as the company described it on LinkedIn
A Natera director's own account of what the designation does and does not confer.
OncoDaily
The clearest plain-language boundary between a designation and a marketing authorization.
NHS-Galleri: primary results from the first randomized multi-cancer screening trial
140,000 participants, published in the New England Journal of Medicine and Nature Medicine: the combined stage III/IV primary endpoint was not met, though stage IV diagnoses fell in later rounds.
Queen Mary University of London
The evidence base a Natera screening claim will be measured against — and the endpoint it has not yet beaten.